Article info

Download PDFPDF
Implication of baseline levels and early changes of C-reactive protein for subsequent clinical outcomes of patients with rheumatoid arthritis treated with tocilizumab

Authors

  1. Correspondence to Professor Daniel Aletaha, Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, 1090 Vienna, Austria; daniel.aletaha{at}meduniwien.ac.at
View Full Text

Citation

Shafran IH, Alasti F, Smolen JS, et al
Implication of baseline levels and early changes of C-reactive protein for subsequent clinical outcomes of patients with rheumatoid arthritis treated with tocilizumab

Publication history

  • Received July 9, 2019
  • Revised March 31, 2020
  • Accepted April 6, 2020
  • First published May 5, 2020.
Online issue publication 
June 14, 2020

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.